Latest Breaking News On - Therapeutics company profile - Page 14 : vimarsana.com

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1 4%

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1 4%
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Zurcher kantonalbank zurich cantonalbankSamarth kulkarniRaju prasadTherapeutics company profileBluepath capital managementMirae asset global investments coSecurities exchange commissionRoyal bankStratos wealth partnersWolfe researchRaymond james financial services advisors incGet free reportExchange commissionJames financial services advisorsWealth partnersKantonalbank zurich cantonalbank

Viking Therapeutics, Inc (NASDAQ:VKTX) CFO Sells $4,986,005 64 in Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CFO Greg Zante sold 66,756 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $74.69, for a total value of $4,986,005.64. Following the completion of the sale, the chief financial officer now owns 174,854 shares of […]

United statesStifel nicolausRaymond jamesGreg zanteTherapeutics company profileGoldman sachs group incMassachusetts financial services coCharles schwab investment management incTherapeutics incMaxim groupSecurities exchange commissionAmerican century companies incViking therapeuticsGet free reportExchange commissionCentury companies

G1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLC

G1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesRajesh malikTherapeutics company profileNeedham companyAlgert globalTherapeutics incCreative financial designs incAcadian asset managementConnor clark lunn investment management ltdGet free reportFinancial designsLunn investment managementAsset management

RAPT Therapeutics, Inc (NASDAQ:RAPT) Receives $25 67 Average Target Price from Analysts

RAPT Therapeutics, Inc (NASDAQ:RAPT) Receives $25 67 Average Target Price from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesTherapeutics incRapt therapeutics incSchonfeld strategic advisorsJpmorgan chase coWolfe researchCantor fitzgeraldSwiss national bankTd asset management incHennion walsh asset management incTherapeutics company profileGet free reportManagement incWalsh asset managementNational bankStrategic advisors

PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Morgan Stanley

PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Morgan Stanley
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesMatthewb kleinTherapeutics company profileNisa investment advisorsJefferies financial groupCantor fitzgeraldTherapeutics incChina universal asset management coAllspring global investments holdingsSecurities exchange commissionHexagon capital partnersRoyal bankMorgan stanleyHeadlands technologiesFree reportFinancial group